A Phase 3 interventional study of MSB11456 and EU-approved RoActemra in Rheumatoid Arthritis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 85 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.
Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 2 that started in 2020, is one of 65 in phase 3, and was the 102nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 604 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Fresenius Kabi SwissBioSim GmbH, one of the names counted as Fresenius Kabi. Under that name alone:
Fresenius Kabi SwissBioSim GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Fresenius Kabi has 8 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis.
Participants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has had any infection as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MSB11456
Drug: EU-approved RoActemra
Participants will receive MSB11456 subcutaneously, once a week.
Participants will receive EU-approved RoActemra® subcutaneously, once a week.
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: Tender Joint Count (TJC), Swollen Joint Count (SJC), erythrocyte sedimentation rate (ESR) and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement.
Time frame: Baseline; Week 24
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: TJC, SJC, ESR and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement. For weeks 30, 42 and 52, the extended baseline (week 24) was used for the change in DAS28-ESR calculation.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16; Extended Period Baseline (Week 24), Week 30, Week 42, and Week 52
Number of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response
ACR20 was defined as the number of participants with at least 20% improvement from baseline in number of tender and swollen joints (68/66 joint count), and at least 20% improvement from baseline in three or more of the 5 ACR Core Set measures: * Patient's Assessment of Arthritis Pain * Physical Function Assessment (Health Assessment Questionnaire-Disability Index) * Acute phase reactant level (erythrocyte sedimentation rate or C-reactive protein) * Patient's Global Assessment of Disease Activity and * Physician's Global Assessment of Disease Activity
Time frame: Baseline; Week 24
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)
Time frame: Baseline to end of study, up to Week 63
Number of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE)
Time frame: Baseline to end of study, up to Week 63
Percentage of Participants With Positive Anti-Drug Antibodies (ADAs)
Time frame: Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55
Anti-Drug Antibodies (ADAs) Titer Levels
Time frame: Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55
Percentage of Participants With Neutralizing Antibodies (NAb)
Time frame: Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55
| Milestone | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra® |
|---|---|---|---|---|---|
| Started | 302 | 302 | 0 | 0 | 0 |
| Received treatment | 302 | 302 | 0 | 0 | 0 |
| Completed | 267 | 276 | 0 | 0 | 0 |
| Not completed | 35 | 26 | 0 | 0 | 0 |
| Withdrew: Adverse event | 14 | 10 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 16 | 9 | 0 | 0 | 0 |
| Withdrew: Discontinued treatment prior to week 24 | 4 | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal by sponsor's decision | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject did not meet eligibility but was randomized | 0 | 1 | 0 | 0 | 0 |
| Milestone | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra® |
|---|---|---|---|---|---|
| Started | 0 | 0 | 267 | 139 | 137 |
| Received treatment | 0 | 0 | 266 | 139 | 136 |
| Completed | 0 | 0 | 244 | 123 | 122 |
| Not completed | 0 | 0 | 23 | 16 | 15 |
| Withdrew: Adverse event | 0 | 0 | 13 | 8 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 4 | 6 |
| Withdrew: Miscellaneous | 0 | 0 | 3 | 2 | 1 |
The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: Tender Joint Count (TJC), Swollen Joint Count (SJC), erythrocyte sedimentation rate (ESR) and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement.
| score on a scale | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® |
|---|---|---|
| Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) | -3.53 ± 0.106 | -3.54 ± 0.106 |
The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: TJC, SJC, ESR and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement. For weeks 30, 42 and 52, the extended baseline (week 24) was used for the change in DAS28-ESR calculation.
| score on a scale | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra® |
|---|---|---|---|---|---|
| Week 2 | -1.24 ± 1.022 | -1.21 ± 0.949 | — | — | — |
| Week 4 | -1.96 ± 1.184 | -1.98 ± 1.135 | — | — | — |
| Week 8 | -2.75 ± 1.220 | -2.69 ± 1.260 | — | — | — |
| Week 12 | -3.13 ± 1.249 | -3.09 ± 1.279 | — | — | — |
| Week 16 | -3.41 ± 1.288 | -3.32 ± 1.242 | — | — | — |
| Week 30 | — | — | -0.16 ± 0.801 | -0.13 ± 0.756 | -0.02 ± 0.863 |
| Week 42 | — | — | -0.34 ± 1.042 | -0.08 ± 1.026 | -0.27 ± 1.031 |
| Week 52 | — | — | -0.42 ± 1.185 | -0.31 ± 1.064 | -0.37 ± 1.086 |
ACR20 was defined as the number of participants with at least 20% improvement from baseline in number of tender and swollen joints (68/66 joint count), and at least 20% improvement from baseline in three or more of the 5 ACR Core Set measures: * Patient's Assessment of Arthritis Pain * Physical Function Assessment (Health Assessment Questionnaire-Disability Index) * Acute phase reactant level (erythrocyte sedimentation rate or C-reactive protein) * Patient's Global Assessment of Disease Activity and * Physician's Global Assessment of Disease Activity
| Participants | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® |
|---|---|---|
| Number of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response | 244 | 256 |
| Participants | MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | EU-approved RoActemra® |
|---|---|---|---|
| Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE) | 237 | 105 | 125 |
| Participants | MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | EU-approved RoActemra® |
|---|---|---|---|
| Number of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE) | 51 | 20 | 33 |
| percentage of participants | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra® |
|---|---|---|---|---|---|
| Overall (includes all time points expect Baseline) | 96.0 | 96.3 | 97.4 | 97.1 | 94.1 |
| Baseline | 6.6 | 8.3 | — | — | — |
| Week 2 | 87.1 | 88.7 | — | — | — |
| Week 12 | 79.0 | 74.3 | — | — | — |
| Week 24 (Extended Treatment Period Baseline) | 76.3 | 68.6 | 86.8 | 77.7 | 87.5 |
| Week 30 | — | — | 76.7 | 73.1 | 65.9 |
| Week 52 | — | — | 80.9 | 76.8 | 61.1 |
| Week 55 | — | — | 81.4 | 82.8 | 77.9 |
| titer | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra® |
|---|---|---|---|---|---|
| Overall (includes all time points except Baseline) | 106.3 (60 to 15360) | 104.0 (60 to 122880) | 215.4 (60 to 15360) | 166.3 (60 to 15360) | 101.1 (60 to 960) |
| Baseline | 71.4 (60 to 960) | 130.4 (60 to 1920) | — | — | — |
| Week 2 | 81.2 (60 to 1920) | 88.1 (60 to 15360) | — | — | — |
| Week 12 | 113.8 (60 to 960) | 123.1 (60 to 122880) | — | — | — |
| Week 24 (Extended Treatment Period Baseline) | 138.4 (60 to 15360) | 102.9 (60 to 1920) | 127.7 (60 to 15360) | 106.1 (60 to 1920) | 95.6 (60 to 960) |
| Week 30 | — | — | 173.0 (60 to 15360) | 130.6 (60 to 7680) | 93.7 (60 to 960) |
| Week 52 | — | — | 230.9 (60 to 7680) | 174.7 (60 to 15360) | 96.7 (60 to 480) |
| Week 55 | — | — | 251.2 (60 to 15360) | 200.8 (60 to 15360) | 112.4 (60 to 480) |
| percentage of participants | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra® |
|---|---|---|---|---|---|
| Overall (includes all time points except Baseline) | 8.4 | 11.3 | 13.2 | 16.8 | 11.9 |
| Baseline | 0 | 0 | — | — | — |
| Week 2 | 3.8 | 3.4 | — | — | — |
| Week 12 | 2.5 | 4.1 | — | — | — |
| Week 24 (Extended Treatment Period Baseline) | 2.9 | 4.9 | 3.8 | 5.8 | 5.9 |
| Week 30 | — | — | 6.1 | 9.7 | 3.0 |
| Week 52 | — | — | 1.6 | 2.4 | 1.6 |
| Week 55 | — | — | 7.0 | 6.6 | 9.0 |
Collected over Day 1 up to Week 63. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSB11456 | 0/302 (0%) | 51/302 (16.9%) | 163/302 (54%) |
| Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | 1/139 (0.7%) | 20/139 (14.4%) | 82/139 (59%) |
| EU-approved RoActemra® | 3/163 (1.8%) | 33/163 (20.2%) | 92/163 (56.4%) |
| Event | MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | EU-approved RoActemra® |
|---|---|---|---|
| COVID-19Infections and infestations | 38/302 | 12/139 | 19/163 |
| Myocardial infarctionCardiac disorders | 1/302 | 1/139 | 0/163 |
| Carotid artery diseaseNervous system disorders | 0/302 | 1/139 | 0/163 |
| CholecystitisHepatobiliary disorders | 0/302 | 1/139 | 0/163 |
| CholelithiasisHepatobiliary disorders | 0/302 | 1/139 | 0/163 |
| Wrist fractureInjury, poisoning and procedural complications | 0/302 | 1/139 | 0/163 |
| Bacterial infectionInfections and infestations | 0/302 | 1/139 | 0/163 |
| Pelvic inflammatory diseaseInfections and infestations | 0/302 | 1/139 | 0/163 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/302 | 1/139 | 0/163 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/302 | 1/139 | 0/163 |
| Event | MSB11456 | Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456 | EU-approved RoActemra® |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 36/302 | 22/139 | 22/163 |
| COVID-19Infections and infestations | 38/302 | 12/139 | 19/163 |
| LeukopeniaBlood and lymphatic system disorders | 22/302 | 8/139 | 12/163 |
| Aspartate aminotransferase increasedInvestigations | 19/302 | 9/139 | 10/163 |
| NeutropeniaBlood and lymphatic system disorders | 19/302 | 8/139 | 10/163 |
| Upper respiratory tract infectionInfections and infestations | 17/302 | 6/139 | 10/163 |
| Blood bilirubin increasedInvestigations | 11/302 | 8/139 | 3/163 |
| HeadacheNervous system disorders | 17/302 | 2/139 | 4/163 |
| NasopharyngitisInfections and infestations | 9/302 | 5/139 | 9/163 |
| Mycobacterium tuberculosis complex test positiveInvestigations | 14/302 | 4/139 | 4/163 |
The Intent-To-Treat (ITT) Analysis Set: includes all randomized participants.
| Age, Continuous(years) | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Total |
|---|---|---|---|
| Mean | 51.2 ± 12.72 | 53.2 ± 11.33 | 52.2 ± 12.08 |
| Sex: Female, Male(Participants) | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Total |
|---|---|---|---|
| Female | 250 | 248 | 498 |
| Male | 52 | 54 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 300 | 300 | 600 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 302 | 302 | 604 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Core Treatment Period: MSB11456 | Core Treatment Period: RoActemra® | Total |
|---|---|---|---|
| Hungary | 19 | 23 | 42 |
| Czechia | 19 | 25 | 44 |
| Poland | 156 | 147 | 303 |
| Moldova | 14 | 9 | 23 |
| Georgia | 43 | 51 | 94 |
| Slovakia | 5 | 1 | 6 |
| Bulgaria | 18 | 16 | 34 |
| Serbia | 7 | 11 | 18 |
| Russia | 21 | 19 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Aug 2021, 12 months.
Results were first posted in Oct 2022, 1 year 1 month after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 12 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab
Fresenius Kabi SwissBioSim GmbH →